This compensatory increase in IL-4 serum levels among MDD patients, as a response to the worldwide rise in pro-inflammatory cytokines, indicates that IL-4 levels in blood evaluation, as opposed to the tracking of pro-inflammatory cytokines, could serve as an appealing diagnostic and prognostic biomarker for MDD. The gene discussed is IL4; the disease is major depressive disorder.